PE20110136A1 - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- PE20110136A1 PE20110136A1 PE2010001194A PE2010001194A PE20110136A1 PE 20110136 A1 PE20110136 A1 PE 20110136A1 PE 2010001194 A PE2010001194 A PE 2010001194A PE 2010001194 A PE2010001194 A PE 2010001194A PE 20110136 A1 PE20110136 A1 PE 20110136A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- benzyl
- oxo
- imidazolidin
- isonicotinamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE P ES DE PREFERENCIA ISONICOTINAMIDA, QUINOLIN-4-CARBOXAMIDA; Q ES DE PREFERENCIA 2-OXO-IMIDAZOLIDIN, 5-OXO-1H-1,2,4-TRIAZOL-4(5H)-IL; R2 ES 4-FLUORO-BENCIL, 4-TRIFLUOROMETIL-BENCIL, BENZO-[c][1,2,5]-TIADIAZOL-5-IL-METIL; 4-TRIFLUOROMETOXI-BENCIL, 3,4-DIFLUORO-BENCIL, ENTRE OTROS; R1 ES 5-METIL-1,3,4-OXADIAZOL-2-IL-METIL, 4-FLUOROBENCIL, 1,3,4-OXADIAZOL-2-IL, PIRIDIN-2-IL-METIL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(3-(4-FLUORO-BENCIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-((5-METIL-1,3,4-OXADIAZOL-2-IL)-METIL)-ISONICOTINAMIDA; 2-(3-(BENZO-[c][1,2,5]-TIADIAZOL-5-IL-METIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-BENCIL-ISONICOTINAMIDA; 2-(3-(4-FLUORO-BENCIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-(PIRIDIN-2-IL-METIL)-QUINOLIN-4-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ESTEAROIL-CoA-DESATURASA (SCD) UTILES EN EL TRATAMIENTO DE DISLIPIDEMIAS Y TRASTORNOS DEL METABOLISMO DE LIPIDOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7644308P | 2008-06-27 | 2008-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110136A1 true PE20110136A1 (es) | 2011-03-17 |
Family
ID=41445023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010001194A PE20110136A1 (es) | 2008-06-27 | 2009-06-25 | Compuestos organicos |
Country Status (25)
Country | Link |
---|---|
US (2) | US9187426B2 (es) |
EP (1) | EP2307379A2 (es) |
JP (1) | JP5529124B2 (es) |
KR (2) | KR20130084328A (es) |
CN (1) | CN102119152B (es) |
AU (1) | AU2009264242A1 (es) |
BR (1) | BRPI0913966A2 (es) |
CA (1) | CA2729327C (es) |
CL (1) | CL2010001526A1 (es) |
CO (1) | CO6341563A2 (es) |
CR (1) | CR11862A (es) |
CU (1) | CU23914B1 (es) |
EA (1) | EA201100049A1 (es) |
EC (1) | ECSP11010787A (es) |
GT (1) | GT201000376A (es) |
HN (1) | HN2010002774A (es) |
IL (1) | IL210118A0 (es) |
MA (1) | MA32508B1 (es) |
MX (1) | MX2010014572A (es) |
NZ (1) | NZ589962A (es) |
PE (1) | PE20110136A1 (es) |
SG (1) | SG192439A1 (es) |
SV (1) | SV2010003777A (es) |
WO (1) | WO2009156484A2 (es) |
ZA (1) | ZA201008951B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR062360A1 (es) | 2006-08-15 | 2008-11-05 | Novartis Ag | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa |
WO2008112164A2 (en) | 2007-03-08 | 2008-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
KR101584826B1 (ko) | 2008-02-20 | 2016-01-18 | 노파르티스 아게 | 스테아로일-CoA 데새투라제의 헤테로시클릭 억제제 |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
WO2010028175A1 (en) | 2008-09-08 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
CN102202669A (zh) | 2008-10-28 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | 醛脱氢酶调节剂及其使用方法 |
EP2358371B1 (en) * | 2008-10-31 | 2015-02-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
SG176105A1 (en) | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
CN103249721B (zh) * | 2010-10-18 | 2016-10-12 | 拉夸里亚创药株式会社 | 作为ttx-s阻滞剂的芳胺衍生物 |
CN103391718A (zh) | 2010-12-06 | 2013-11-13 | 汇合生命科学股份有限公司 | 取代的吡啶酮-吡啶基化合物 |
US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CA2828524C (en) | 2011-02-28 | 2020-01-07 | Repligen Corporation | Histone deacetylase inhibitors |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
RU2014108140A (ru) | 2011-08-04 | 2015-09-10 | Эррэй Биофарма Инк. | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ |
US20130165472A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
TWI589569B (zh) | 2012-03-01 | 2017-07-01 | 亞雷生物製藥股份有限公司 | 絲胺酸/酥胺酸激酶抑制劑 |
WO2013176970A1 (en) * | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US9388171B2 (en) | 2012-08-27 | 2016-07-12 | Genetech, Inc. | Serine/threonine kinase inhibitors |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2014160185A2 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
AU2014228344C1 (en) | 2013-03-15 | 2019-02-07 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
JP6699909B2 (ja) | 2013-06-07 | 2020-05-27 | アクラリス セラピューティクス,インコーポレイテッド | メチル/フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物 |
EP3126362B1 (en) | 2014-04-02 | 2022-01-12 | Intermune, Inc. | Anti-fibrotic pyridinones |
EP3177611B1 (en) | 2014-08-04 | 2021-10-06 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
WO2017043341A1 (ja) * | 2015-09-08 | 2017-03-16 | 住友化学株式会社 | トリアゾール化合物 |
US9796699B2 (en) | 2015-11-03 | 2017-10-24 | Janssen Pharmaceutica Nv | Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same |
IL304017A (en) | 2017-01-06 | 2023-08-01 | Yumanity Therapeutics Inc | Methods for treating neurological disorders |
US9951069B1 (en) | 2017-01-11 | 2018-04-24 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
WO2018235851A1 (en) * | 2017-06-20 | 2018-12-27 | Raqualia Pharma Inc. | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS |
CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
US20220213088A1 (en) * | 2019-04-30 | 2022-07-07 | Valo Health, Inc. | Inhibiting usp36 |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3172203A1 (en) | 2020-03-27 | 2021-09-30 | Gary A. Decrescenzo | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6133172A (ja) | 1984-07-24 | 1986-02-17 | Kotobuki Seiyaku Kk | 1,3−置換−2−イミダゾリジノン誘導体,胃腸運動亢進剤及びその製造方法 |
US4600430A (en) * | 1985-02-22 | 1986-07-15 | Eli Lilly And Company | Pyridinylimidazolidinone compounds |
JPH0249725A (ja) | 1988-05-13 | 1990-02-20 | Tanabe Seiyaku Co Ltd | 脳代謝賦活剤 |
JP3916092B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
US5607932A (en) * | 1994-07-12 | 1997-03-04 | Janssen Pharmaceutica N.V. | Heterocyclic derivatives of azolones |
DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
MXPA01009805A (es) | 1999-03-29 | 2004-07-30 | Univ Ulster | Peptido. |
CZ296858B6 (cs) | 1999-09-28 | 2006-07-12 | Bayer Corporation | Agonisté receptoru 3 (R3) hypofyzárního peptidu aktivujícího adenylátcyklázu (PACAP) a jejich farmaceutické pouzití |
EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
CA2411859A1 (en) * | 2000-06-05 | 2001-12-13 | Jae-Gul Lee | Novel oxazolidinone derivatives and a process for the preparation thereof |
DE60134995D1 (de) | 2000-09-26 | 2008-09-04 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
JP2004107323A (ja) | 2002-07-26 | 2004-04-08 | Nippon Nohyaku Co Ltd | 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法 |
US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
MXPA04012948A (es) * | 2002-07-31 | 2005-09-12 | Schering Ag | Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3. |
BRPI0515505A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase |
EP2316457A1 (en) * | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
EP2540296A1 (en) * | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
-
2009
- 2009-06-25 PE PE2010001194A patent/PE20110136A1/es not_active Application Discontinuation
- 2009-06-25 CA CA2729327A patent/CA2729327C/en not_active Expired - Fee Related
- 2009-06-25 KR KR1020137017503A patent/KR20130084328A/ko not_active Application Discontinuation
- 2009-06-25 SG SG2013049614A patent/SG192439A1/en unknown
- 2009-06-25 NZ NZ589962A patent/NZ589962A/xx not_active IP Right Cessation
- 2009-06-25 CN CN200980131152.2A patent/CN102119152B/zh not_active Expired - Fee Related
- 2009-06-25 US US13/000,413 patent/US9187426B2/en not_active Expired - Fee Related
- 2009-06-25 AU AU2009264242A patent/AU2009264242A1/en not_active Abandoned
- 2009-06-25 MX MX2010014572A patent/MX2010014572A/es not_active Application Discontinuation
- 2009-06-25 JP JP2011515392A patent/JP5529124B2/ja not_active Expired - Fee Related
- 2009-06-25 WO PCT/EP2009/057998 patent/WO2009156484A2/en active Application Filing
- 2009-06-25 BR BRPI0913966A patent/BRPI0913966A2/pt not_active IP Right Cessation
- 2009-06-25 EA EA201100049A patent/EA201100049A1/ru unknown
- 2009-06-25 EP EP09769332.9A patent/EP2307379A2/en not_active Withdrawn
- 2009-06-25 KR KR1020117002017A patent/KR20110022089A/ko not_active Application Discontinuation
-
2010
- 2010-12-13 ZA ZA2010/08951A patent/ZA201008951B/en unknown
- 2010-12-20 IL IL210118A patent/IL210118A0/en unknown
- 2010-12-21 SV SV2010003777A patent/SV2010003777A/es unknown
- 2010-12-21 CR CR11862A patent/CR11862A/es not_active Application Discontinuation
- 2010-12-23 CL CL2010001526A patent/CL2010001526A1/es unknown
- 2010-12-24 HN HN2010002774A patent/HN2010002774A/es unknown
- 2010-12-27 GT GT201000376A patent/GT201000376A/es unknown
- 2010-12-27 CU CU2010000262A patent/CU23914B1/es not_active IP Right Cessation
-
2011
- 2011-01-26 MA MA33563A patent/MA32508B1/fr unknown
- 2011-01-27 EC EC2011010787A patent/ECSP11010787A/es unknown
- 2011-01-27 CO CO11009246A patent/CO6341563A2/es active IP Right Grant
-
2015
- 2015-10-09 US US14/879,583 patent/US20160289191A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CR11862A (es) | 2011-02-16 |
WO2009156484A3 (en) | 2010-05-14 |
US20160289191A1 (en) | 2016-10-06 |
HN2010002774A (es) | 2013-01-28 |
CA2729327C (en) | 2016-10-11 |
GT201000376A (es) | 2013-09-09 |
NZ589962A (en) | 2012-12-21 |
CN102119152B (zh) | 2014-07-02 |
EP2307379A2 (en) | 2011-04-13 |
SG192439A1 (en) | 2013-08-30 |
WO2009156484A2 (en) | 2009-12-30 |
IL210118A0 (en) | 2011-02-28 |
AU2009264242A1 (en) | 2009-12-30 |
US20110105530A1 (en) | 2011-05-05 |
JP5529124B2 (ja) | 2014-06-25 |
MX2010014572A (es) | 2011-03-24 |
MA32508B1 (fr) | 2011-07-03 |
JP2011525896A (ja) | 2011-09-29 |
ECSP11010787A (es) | 2011-02-28 |
CN102119152A (zh) | 2011-07-06 |
ZA201008951B (en) | 2012-02-29 |
KR20110022089A (ko) | 2011-03-04 |
SV2010003777A (es) | 2011-07-05 |
CO6341563A2 (es) | 2011-11-21 |
US9187426B2 (en) | 2015-11-17 |
CL2010001526A1 (es) | 2011-07-01 |
BRPI0913966A2 (pt) | 2015-11-17 |
EA201100049A1 (ru) | 2011-08-30 |
CU20100262A7 (es) | 2011-11-15 |
CA2729327A1 (en) | 2009-12-30 |
CU23914B1 (es) | 2013-07-31 |
KR20130084328A (ko) | 2013-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110136A1 (es) | Compuestos organicos | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20091828A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2 | |
PE20121732A1 (es) | Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes | |
PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
PE20141120A1 (es) | Compuestos heterociclicos | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
PE20140934A1 (es) | Derivados de pirazol | |
PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
PE20130405A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20150636A1 (es) | Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido | |
PE20091486A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k | |
PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |